ISPOR - EE353 An Analysis of Stakeholders’ Contribution to High-WAC and Low-WAC Adalimumab Products in 2025 Under the Inflation Reduction Act in the United States

EE353 An Analysis of Stakeholders’ Contribution to High-WAC and Low-WAC Adalimumab Products in 2025 Under the Inflation Reduction Act in the United States

Abstract

Authors

H Yoo M Jang T Kwon

Full Text Cite This Article

Back to Volume 27, Supplemental Issue 6S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now